T2 Biosystems Showcases Research from Recent Industry Conferences
“We are committed to the generation of clinical data to support the adoption and utilization of our rapid diagnostic technology, especially when it comes to bloodstream infections (BSI) and sepsis,” said
Across three industry conferences in September – the American Association for Clinical Chemistry’s (AACC) Annual Scientific Meeting and Clinical Lab Expo; the
- Literature review evaluating the impact of T2MR® culture-independent rapid diagnostics on accuracy of lab results, time to diagnosis of blood stream infections, impact on patientcare outcomes.
- Results show T2Candida® and T2Bacteria® Panels provide rapid, specific and sensitive detection of bloodstream infections caused by pathogens commonly implicated in BSI that progress to sepsis.
- Performance of both assays demonstrated high accuracy with overall sensitivity and specificity of T2Candida® at 91.1% and 99.4% and T2Bacteria® at 90% and 98%, respectively.
- T2 Panels provided opportunity to initiate faster targeted therapy, de-escalation, shorter ICU and hospital length of stay and antimicrobial cost savings.
Performance of the T2Resistance® Panel in Whole Blood, and Implications for Improving Appropriate Therapy of Bloodstream Infections – Presented by Abigail Skeel, Researcher at
- Evaluation of the performance of the T2Resistance® Panel in detecting targeted resistance markers in patients with bloodstream infections due to ESKAPE pathogens and the potential impact on time to appropriate antibiotic therapy.
The T2Resistance Paneldemonstrated sensitivity of 92% to 100% and specificity of 99% to 100% as compared to sequencing, detected resistance determinants in three to seven hours, and has the potential to significantly shorten time to appropriate antibiotics.
Development of a Rapid, High Sensitivity, Direct from Blood Assay for Identification of Biothreat Organisms – Presented by
- Discussion of the development of an in vitro diagnostic assay for the identification of biothreat organisms direct from a patient blood sample.
- Achievement of sensitive and specific detection of six
CDCCategory A or Category B bacterial biothreat species directly from blood samples in less than five hours using T2 Biosystems’ T2Dx® Instrument.
- Review of the analysis of SARS-CoV-2 sequences confirms that the Company’s
T2SARS-CoV-2 Paneldetects all currently documented COVID-19 variants, resulting in a routine screening methodology to confirm detection of emerging novel variants.
Utilization of a Novel Diagnostic Assay to Improve Turnaround Time and Accurate Diagnosis and Treatment of Secondary Candidemia in a Critically Ill Immunosuppressed COVID-19 Patient – Presented by
- Case study highlights the utilization of the T2Candida® Panel for timely and accurate diagnosis of candidemia in a critically ill patient with COVID-19 resulting in rapid initiation of targeted antifungal therapy and a positive outcome for the patient.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the development of clinical data to support the adoption and utilization of our rapid diagnostic technology, as well as statements that include the words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”, “estimate,” “may,” “should,” “anticipate,” and similar statements of a future or forward looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended
Source: T2 Biosystems, Inc.